Get the Stockscreener App
18.58
0.11%
-0.06
Elanco Animal Health Inc stock is traded at $18.58, with a volume of 30,702.
It is down -0.11% in the last 24 hours and up +3.67% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$18.64
Open:
$18.56
24h Volume:
30,702
Relative Volume:
0.00
Market Cap:
$9.22B
Revenue:
$4.45B
Net Income/Loss:
$205.00M
P/E Ratio:
46.45
EPS:
0.4
Net Cash Flow:
$372.00M
1W Performance:
-0.75%
1M Performance:
+3.67%
6M Performance:
+78.34%
1Y Performance:
+28.14%
1-Day Range:
$18.53
$18.65
1-Week Range:
$18.22
$18.94
52-Week Range:
$8.02
$19.07
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
2500 INNOVATION WAY, GREENFIELD
Compare ELAN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
18.56 | 9.26B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
147.07 | 64.82B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.12 | 47.56B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.34 | 43.31B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.82 | 21.67B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
401.32 | 18.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Elanco Animal Health Incorporated $ELAN Shares Sold by Teza Capital Management LLC - MarketBeat
Institution Moves: Can Elanco Animal Health Incorporated ride the EV waveWeekly Investment Report & Stepwise Entry/Exit Trade Alerts - خودرو بانک
Elanco Animal Health Incorporated $ELAN Holdings Decreased by Douglas Lane & Associates LLC - MarketBeat
Guidance Update: What analysts say about Elanco Animal Health Incorporated stockJuly 2025 Final Week & Accurate Entry/Exit Alerts - خودرو بانک
Buybacks Report: Can Elanco Animal Health Incorporated reach all time highs this yearWeekly Investment Recap & Reliable Intraday Trade Alerts - خودرو بانک
Institution Moves: Is Elanco Animal Health Incorporated forming a bullish divergence2025 Support & Resistance & Technical Pattern Based Signals - خودرو بانک
Quarterly Earnings: What is the PEG ratio of Elanco Animal Health Incorporated2025 Biggest Moves & Precise Buy Zone Tips - خودرو بانک
Great Lakes Advisors LLC Reduces Stock Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Incorporated $ELAN Holdings Raised by AQR Capital Management LLC - MarketBeat
Elanco Animal Health (NYSE:ELAN) Hits New 52-Week HighWhat's Next? - MarketBeat
Elanco (ELAN) Jumps 19.7% to Record High on Earnings Boost - MSN
Comerica Bank Grows Stock Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Makes Strides With New Companion Animal Products - Morningstar
Hsbc Holdings PLC Has $248,000 Stock Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco CEO Says Blockbuster Drugs Driving Business - MarketScreener
Elanco at Morgan Stanley Conference: Strategic Growth Insights - Investing.com
Why Elanco (ELAN) Stock Is Trading Up Today - Yahoo Finance
Elanco Animal Health stock hits 52-week high at $18.88 By Investing.com - Investing.com Canada
Elanco Animal Health’s Valuation in Focus After Breakthroughs for Credelio Quattro and Zenrelia Products - Yahoo Finance
Elanco’s Credelio Quattro hits $100 million sales milestone By Investing.com - Investing.com Canada
Elanco’s Credelio Quattro hits $100 million sales milestone - Investing.com
Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status - PR Newswire
Companion Animal Health Market is expected to reach US$ 56.60 - openPR.com
Leerink Partnrs Has Strong Outlook for ELAN FY2027 Earnings - MarketBeat
State’s exit from GM site ownership signals new economic development approach - Inside INdiana Business
Using data models to predict Elanco Animal Health Incorporated stock movementSwing Trade & Daily Stock Trend Reports - Newser
How do insiders feel about Elanco Animal Health IncorporatedGlobal Markets & AI Driven Stock Reports - خودرو بانک
State of Wyoming Boosts Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
What’s the outlook for Elanco Animal Health Incorporated’s sector2025 Fundamental Recap & Weekly Breakout Watchlists - خودرو بانک
Can you recover from losses in Elanco Animal Health Incorporated2025 Market Trends & Fast Entry High Yield Stock Tips - Newser
Can Elanco Animal Health Incorporated recover in the next quarterQuarterly Performance Summary & Target Return Focused Stock Picks - Newser
How to use a screener to detect Elanco Animal Health Incorporated breakoutsJuly 2025 Fed Impact & Weekly High Return Opportunities - Newser
Analyzing recovery setups for Elanco Animal Health Incorporated investorsMarket Growth Review & Capital Protection Trade Alerts - Newser
Future of Animal Parasiticides Market: Sustainable - openPR.com
Tools to monitor Elanco Animal Health Incorporated recovery probabilityPortfolio Return Report & Stock Portfolio Risk Management - Newser
Elanco (ELAN) Q2 Revenue Jumps 5% - AOL.com
Can momentum traders help lift Elanco Animal Health IncorporatedAnalyst Upgrade & Daily Profit Focused Stock Screening - Newser
Should you wait for a breakout in Elanco Animal Health Incorporated2025 Trading Recap & Precise Trade Entry Recommendations - Newser
Poultry Antibiotic Market to Witness Massive Growth by 2032 | - openPR.com
What indicators show strength in Elanco Animal Health IncorporatedJuly 2025 Breakouts & Weekly High Potential Stock Alerts - Newser
Will Elanco Animal Health Incorporated outperform the marketTrade Analysis Report & Expert-Curated Trade Recommendations - Newser
Will Elanco Animal Health Incorporated benefit from current market trendsPortfolio Gains Summary & Safe Capital Growth Tips - خودرو بانک
Can volume confirm reversal in Elanco Animal Health Incorporated2025 Earnings Impact & Low Volatility Stock Recommendations - Newser
Why Elanco (ELAN) Stock Is Trading Lower Today - Yahoo Finance
Is Elanco Animal Health Incorporated a good ESG investmentMarket Sentiment Review & Proven Capital Preservation Tips - خودرو بانک
Buyout Rumor: What is Elanco Animal Health Incorporated s P E ratio telling usEarnings Miss & Weekly High Momentum Picks - خودرو بانک
Smart tools for monitoring Elanco Animal Health Incorporated’s price action2025 Valuation Update & High Yield Stock Recommendations - Newser
Using data tools to time your Elanco Animal Health Incorporated exitPortfolio Value Summary & Accurate Buy Signal Alerts - Newser
Veterinary Oncology Market Shares, Competition and Trends Analysis 2025-2030: Discover the Impact of Advanced Therapies and Digital Tools - GlobeNewswire Inc.
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.56%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):